Lunai Bioworks Inc. 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences Inc. (Exact name of registrant as specified in its charter) Delaware 45-2559340 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 1927 Paseo Rancho Castillo Los Angeles , CA 90032 (Address of principal executive offices) (Zip Code) +1 (305) 918-1980 (Registrant’s telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 per share ENOB The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of March 9, 2023, the number of shares of the registrant’s common stock outstanding was 55,705,521 . ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES - INDEX - Page PART I – FINANCIAL INFORMATION: 1 Item 1. Financial Statements (Unaudited): 1 Condensed Consolidated Balance Sheets as of December 31, 2022 (Unaudited) and June 30, 2022 2 Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2022, and 2021 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended December 31, 2022, and 2021 (Unaudited) 4 Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended December 31, 2022, and 2021 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2022, and 2021 (Unaudited) 7 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3. Quantitative and Qualitative Disclosures About Market Risk 33 Item 4. Controls and Procedures 33 PART II – OTHER INFORMATION: 34 Item 1. Legal Proceedings 34 Item 1A. Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 35 Signatures 36 i PART I – FINANCIAL INFORMATION Item 1. Financial Statements. The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented. The results for the periods ended December 31, 2022, are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form 10-K for the fiscal year ended June 30, 2022, filed with the Securities and Exchange Commission on February 27, 2023. 1 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, June 30, 2022 2022 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 4,118,896 $ 9,172,142 Prepaids and other assets 1,270,575 392,996 Total Current Assets 5,389,471 9,565,138 Property and equipment, net 555,916 586,536 OTHER ASSETS: Definite life intangible assets, net 42,084 44,268 Indefinite life intangible assets, net 61,571,000 61,571,000 Goodwill 11,640,000 11,640,000 Deposits and other assets 61,936 68,635 Operating lease right-of-use assets 1,013,256 1,157,086 Total Other Assets 74,328,276 74,480,989 TOTAL ASSETS $ 80,273,663 $ 84,632,663 LIABILITIES CURRENT LIABILITIES: Accounts payable – trade $ 4,555,226 $ 1,401,867 Accrued expenses 932,603 1,031,462 Other current liabilities 875,415 220,685 Contingent consideration liability — 2,343,318 Notes payable, net 4,726,390 — Convertible notes payable — 1,200,000 Current portion of operating lease liabilities 202,370 253,636 Total Current Liabilities 11,292,004 6,450,968 NON-CURRENT LIABILITIES: Convertible notes payable 1,200,000 — Notes payable, net — 4,577,148 Operating lease liabilities, net of current portion 882,303 985,699 Total Non-Current Liabilities 2,082,303 5,562,847 Total Liabilities 13,374,307 12,013,815 Commitments and Contingencies — — STOCKHOLDERS’ EQUITY: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock, par value $ 0.0001 , 100,000,000 shares authorized, 55,705,521 shares issued and outstanding at December 31, 2022, and 53,007,082 shares issued and outstanding at June 30, 2022 5,572 5,302 Additional paid-in capital 283,426,764 276,989,179 Accumulated deficit ( 216,502,705 ) ( 204,345,197 ) Accumulated other comprehensive loss ( 30,275 ) ( 30,436 ) Total Stockholders’ Equity 66,899,356 72,618,848 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 80,273,663 $ 84,632,663 See accompanying notes to the unaudited condensed consolidated financial statements. 2 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Six Months Ended December 31, December 31, 2022 2021 2022 2021 Operating Expenses General and administrative $ 4,013,063 $ 3,961,764 $ 8,569,903 $ 8,379,268 Research and development 325,959 2,337,222 2,931,334 5,392,658 Depreciation and amortization 28,844 31,805 57,245 63,538 Total Operating Expenses 4,367,866 6,330,791 11,558,482 13,835,464 LOSS FROM OPERATIONS ( 4,367,866 ) ( 6,330,791 ) ( 11,558,482 ) ( 13,835,464 ) Other Income (Expense) Loss on extinguishment of contingent consideration — — ( 419,182 ) — Change in fair value of contingent consideration — ( 167,255 ) — ( 2,991,897 ) Interest expense ( 92,892 ) ( 93,382 ) ( 188,477 ) ( 183,121 ) Gain on currency transactions — — — 9 Interest and other income 3,010 8,487 8,633 15,597 Total Other Income (Expense) ( 89,882 ) ( 252,150 ) ( 599,026 ) ( 3,159,412 ) Loss Before Income Taxes ( 4,457,748 ) ( 6,582,941 ) ( 12,157,508 ) ( 16,994,876 ) Income Tax (Provision) Benefit — — — ( 34 ) NET LOSS $ ( 4,457,748 ) $ ( 6,582,941 ) $ ( 12,157,508 ) $ ( 16,994,910 ) BASIC AND DILUTED LOSS PER SHARE $ ( 0.08 ) $ ( 0.13 ) $ ( 0.22 ) $ ( 0.33 ) WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED 55,509,239 52,321,982 55,304,356 52,270,821 See accompanying notes to the unaudited condensed consolidated financial statements. 3 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) For the Three Months Ended For the Six Months Ended December 31, December 31, 2022 2021 2022 2021 Net Loss $ ( 4,457,748 ) $ ( 6,582,941 ) $ ( 12,157,508 ) $ ( 16,994,910 ) Other Comprehensive Income (Loss) Foreign currency translation, net of taxes 7,915 ( 3,990 ) 161 ( 7,983 ) Comprehensive Loss $ ( 4,449,833 ) $ ( 6,586,931 ) $ ( 12,157,347 ) $ ( 17,002,893 ) See accompanying notes to the unaudited condensed consolidated financial statements. 4 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) # of Shares Common Shares Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income Total July 1, 2022 53,007,082 $ 5,302 $ 276,989,179 $ ( 204,345,197 ) $ ( 30,436 ) $ 72,618,848 Stock issued pursuant to warrants exercised 1,250,000 125 1,624,875 1,625,000 Shares issued for earn-out 1,250,000 125 2,762,375 2,762,500 Stock-based compensation — — 1,026,008 — — 1,026,008 Net Loss — — — ( 7,699,760 ) — ( 7,699,760 ) Foreign currency translation adjustment — — — — ( 7,754 ) ( 7,754 ) September 30, 2022 55,507,082 $ 5,552 $ 282,402,437 $ ( 212,044,957 ) $ ( 38,190 ) $ 70,324,842 Shares issued in lieu of interest on $1.2 million note payable extension 198,439 20 204,372 — — 204,392 Stock-based compensation — — 819,955 — — 819,955 Net Loss — — — ( 4,457,748 ) — ( 4,457,748 ) Foreign currency translation adjustment — — — — 7,915 7,915 December 31, 2022 55,705,521 $ 5,572 $ 283,426,764 $ ( 216,502,705 ) $ ( 30,275 ) $ 66,899,356 See accompanying notes to the unaudited condensed consolidated financial statements. 5 # of Shares Common Shares Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income Total July 1, 2021 52,219,661 $ 5,222 $ 265,580,356 $ ( 90,911,805 ) $ ( 10,834 ) $ 174,662,939 Stock-based compensation — — 2,727,975 — — 2,727,975 Net Loss — — — ( 10,411,969 ) — ( 10,411,969 ) Foreign currency translation adjustment — — — — ( 3,993 ) ( 3,993 ) September 30, 2021 52,219,661 5,222 268,308,331 ( 101,323,774 ) ( 14,827 ) 166,974,952 Stock issued pursuant to warrants exercised 100,000 10 129,990 — — 130,000 Shares issued pursuant to LPC purchase agreement 277,340 28 3,048,311 — — 3,048,339 Stock-Based Compensation — — 2,043,292 — — 2,043,292 Shares issued for fully vested RSUs 1,266 — 9,811 — — 9,811 Restricted shares converted to shares for services rendered 35,000 3 ( 3 ) — — — Net Loss — — — ( 6,582,941 ) — ( 6,582,941 ) Foreign currency translation adjustment — — — — ( 3,990 ) ( 3,990 ) December 31, 2021 52,633,267 $ 5,263 $ 273,539,732 $ ( 107,906,715 ) $ ( 18,817 ) $ 165,619,463 See accompanying notes to the unaudited condensed consolidated financial statements. 6 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Six Months Ended December 31, 2022 2021 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 12,157,508 ) $ ( 16,994,910 ) ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: Depreciation and amortization 57,245 63,538 Loss on extinguishment of contingent consideration liability 419,182 — Change in contingent consideration liability — 2,991,897 Stock based compensation expense 1,845,963 4,771,267 Amortization of discount of notes payable 149,242 148,548 Changes in assets and liabilities: Other receivables 46 1,640 Prepaid expenses/deposits 425,233 ( 11,812 ) Accounts payable 3,153,358 ( 153,810 ) Accrued expenses ( 68,554 ) ( 677,939 ) Other current liabilities ( 18,520 ) ( 30,004 ) Operating leases, net ( 10,832 ) ( 5,566 ) NET CASH USED IN OPERATING ACTIVITIES ( 6,205,145 ) ( 9,897,151 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment ( 23,633 ) ( 5,156 ) NET CASH USED IN INVESTING ACTIVITIES ( 23,633 ) ( 5,156 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of warrants 1,625,000 130,000 Repayment of finance agreement ( 466,625 ) ( 227,598 ) Proceeds from LPC equity agreement — 3,048,339 NET CASH PROVIDED BY FINANCING ACTIVITIES 1,158,375 2,950,741 Effect of exchange rates on cash 17,157 ( 4,937 ) NET CHANGE IN CASH ( 5,053,246 ) ( 6,956,503 ) CASH, BEGINNING OF PERIOD 9,172,142 20,664,410 CASH, END OF PERIOD $ 4,118,896 $ 13,707,907 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid during the period for: Interest $ 30,332 $ 36,462 Income Taxes $ — $ 34 SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Finance agreement entered into in exchange for prepaid assets $ 1,139,875 $ 666,875 Shares in lieu of interest on $1.2 million notes payable extension $ 204,392 $ — Common shares issued for contingent earn out liability $ 2,762,500 $ — See accompanying notes to the unaudited condensed consolidated financial statement. 7 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business – Enochian Biosciences Inc., (“Enochian,” or “Registrant”, and together with its subsidiaries, the “Company”, “we” or “us”) engages in the research and development of pharmaceutical and biological products for the treatment of Cancer, HIV, and HBV with the intent to manufacture said products. Going Concern - These financial statements have been prepared on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any revenue, has incurred substantial recurring losses from continuing operations and has an accumulated deficit of $ 216,502,705 as of December 31, 2022. The continuation of the Company as a going concern is dependent upon (i) its ability to successfully obtain FDA approval of its product candidates, (ii) its ability to obtain any necessary debt and/or equity financing, and (iii) its ability to generate profits from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Basis of Presentation – The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and follows the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at December 31, 2022, and 2021 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2022, audited financial statements. The results of operations for the periods ended December 31, 2022, and 2021 are not necessarily indicative of the operating results for the full year. Consolidation – For the three and six months ended December 31, 2022, and 2021, the condensed consolidated financial statements include the accounts and operations of the Registrant and its subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation. Reclassification – Certain amounts in the prior period financial statements, have been reclassified to conform to the current presentation. For the three and six months ended December 31, 2021, we reclassified lab expenses of $ 193,137 and $ 242,330 , respectively from general and administrative expenses to research and development expenses . Accounting Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued. COVID-19 Update – The COVID-19 pandemic continues to evolve. COVID-19 may cause delays in our research activities. To date, the COVID-19 pandemic has not materially affected our operations. However, it has caused delays in the conduct of experiments due to limitations in resources and supply chain issues, in particular for those third-parties conducting experiments. There have also been increases in the cost to conduct animal studies due to staffing and other limitations. The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. In addition, the pandemic could result in significant and prolonged disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect the financial resources available to us. Functional Currency & Foreign Currency Translation – The functional currency of Enochian Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ended December 31, 2022, and 2021. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred. 8 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Cash and Cash Equivalents – The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in Denmark and in the United States in excess of federally insured amounts at December 31, 2022, and June 30, 2022, of $ 3,830,530 and $ 8,805,495 , respectively. Property and Equipment – Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets, which range from four to ten years (see Note 4.) Intangible Assets – The Company has both definite and indefinite life intangible assets. Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill – Goodwill is not amortized but is evaluated for impairment annually as of June 30 th of each fiscal year or whenever events or changes in circumstances indicate the carrying value may not be recoverable. Impairment of Goodwill and Indefinite Lived Intangible Assets – We test for goodwill impairment at the reporting unit level, which is one level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair value, we record an impairment loss for such excess. The annual fair value analysis performed on goodwill supported that goodwill was not impaired as of June 30, 2022, and no impairment is deemed necessary as of December 31, 2022 (see Note 5.) For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2022, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 93,253,000 during the year ended June 30, 2022. No additional impairment is deemed necessary as of December 31, 2022 (see Note 5.) The carrying value of IPR&D and goodwill at December 31, 2022, was $ 61,571,000 and $ 11,640,000 , respectively. 9 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Impairment of Long-Lived Assets – Long-lived assets, such as property and equipment, definite and indefinite life intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. Leases – In accordance with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information available at the commencement date in determining the present value of the future payments. Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.) Research and Development Expenses – The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative or modified processes related to and expanding the use of the Oncology, HIV and HBV therapies and technologies for use in the prevention, treatment, amelioration of and/or therapy for Oncology, HIV and HBV. Research and development expenses for the three and six months ended December 31, 2022, amounted to $ 325,959 and $ 2,931,334 , respectively. Research and development expenses for the three and six months ended December 31, 2021, amounted to $ 2,337,222 , and $ 5,392,658 , respectively. Income Taxes – The Company accounts for income taxes in accordance with FASB ASC Topic 740, “Accounting for Income Taxes”, which requires an asset and liability approach for accounting for income taxes. Loss Per Share – The Company calculates earnings/ (loss) per share in accordance with FASB ASC Topic 260, “Earnings Per Share”. Basic earnings per common share (EPS) are based on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive shares of Common Stock. Potential shares of Common Stock included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. Because of the net loss for the three and six months ended December 31, 2022, and 2021, the dilutive shares for both periods were excluded from the Diluted EPS calculation as the effect of these potential shares of Common Stock is anti-dilutive. The Company had 4,833,436 and 7,125,894 potential shares of Common Stock excluded from the Diluted EPS calculation as of December 31, 2022, and December 31, 2021, respectively. 10 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 — THE BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Fair Value of Financial Instruments – The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability (see Note 3.) Stock Options and Restricted Share Units – The Company has granted stock options, restricted share units (“RSUs”) and warrants. The Company accounts for stock-based awards in accordance with the provisions of FASB ASC Topic 718, “Compensation - Stock Compensation”. Stock-Based Compensation – The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation - Stock Compensation”. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued and are recognized over the required service period, which is generally the vesting period. Stock based compensation costs for the vesting of options and RSUs granted for the three and six months ended December 31, 2022, were $ 819,955 and $ 1,845,963 , respectively. Stock-based compensation costs for the vesting of the options and RSUs granted for the three and six months ended December 31, 2021, were $ 2,043,292 and $ 4,771,267 , respectively. (See Note 8.) Recently Adopted Accounting Pronouncements – Recent accounting pronouncements issued by the FASB do not or are not believed by management to have a material impact on the Company’s present or future financial statements. 11 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 – GOING CONCERN The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of approximately $ 4,457,748 and $ 12,157,508 for the three and six months ended December 31, 2022, respectively. As of December 31, 2022, the Company had cash and cash equivalents of $ 4,118,896 and an accumulated deficit of $ 216,502,705 . These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Management intends to raise additional funds for (a) research and development, (b) increases in personnel, and (c) the purchase of equipment, specifically to advance the Company’s potential products through the regulatory process. The Company may raise such funds from time to time through public or private sales of equity or debt securities. Such financing may not be available on acceptable terms, or at all, and the failure to raise capital when needed could materially adversely affect the Company’s growth plans and its financial condition and results of operations. NOTE 3 — FAIR VALUE MEASUREMENTS The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no Level 1, 2 or 3 assets, nor any Level 1, 2 or 3 liabilities measured at fair value on a recurring basis as of December 31, 2022. 12 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following: Summary of property and equipment Useful Life December 31, 2022 June 30, 2022 Lab Equipment and Instruments 4 - 7 $ 570,157 $ 546,524 Leasehold Improvements 10 224,629 224,629 Furniture, Fixtures and Equipment 4 - 7 172,861 172,861 Total 967,647 944,014 Less Accumulated Depreciation ( 411,731 ) ( 357,478 ) Net Property and Equipment $ 555,916 $ 586,536 Depreciation expense amounted to $ 27,338 , and $ 54,253 for the three and six months ended December 31, 2022, respectively, and $ 27,990 and $ 55,796 for the three and six months ended December 31, 2021, respectively. NOTE 5 — INTANGIBLE ASSETS At December 31, 2022, and June 30, 2022, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 42,084 and $ 44,268 , respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three and six months ended December 31, 2022, was $ 1,507 and $ 2,993 , respectively. Amortization expense for the three and six months ended December 31, 2021, was $ 3,814 and $ 7,741 , respectively. At December 31, 2022, and 2021, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill. At December 31, 2022, and June 30, 2022, definite and indefinite-life intangible assets consisted of the following: Schedule of life intangible assets Useful Life June 30, 2022 Period Change Effect of Currency Translation December 31, 2022 Definite Life Intangible Assets Patents 20 Years $ 279,257 $ — $ 6,163 $ 285,420 Less Accumulated Amortization ( 234,989 ) ( 2,993 ) ( 5,354 ) ( 243,336 ) Net Definite-Life Intangible Assets $ 44,268 $ ( 2,993 ) $ 809 $ 42,084 Indefinite Life Intangible Assets License Agreement $ 61,571,000 — — $ 61,571,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 73,211,000 — — $ 73,211,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Year ending June 30, 2023 $ 8,883 2024 11,067 2025 11,067 2026 11,067 Total $ 42,084 During February 2018, the Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment. Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment indicated that the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value, due to the sublicensing of ENOB HV-01, which required a different valuation approach and changes in other factors impacting the fair value of the asset. Therefore, an impairment adjustment of $ 93,253,000 was recorded in the year ended June 30, 2022. No additional impairment is deemed necessary as of December 31, 2022. 13 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 6 — LEASES Operating Leases — On November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $ 70,800 related to leasehold improvements that was not utilized. On June 19, 2018, the Company entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Company entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease expense for the term of the lease is $20,050. The Company subleased the space as of June 25, 2022 (see subsection below “ Sublease Agreement ” for details.) The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities: Expected lease term — The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s lease has a remaining lease term of 56 months. As of December 31, 2022, the weighted-average remaining term is 4.67 years. Incremental borrowing rate — The Company’s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of December 31, 2022, the weighted-average discount rate is 4.03 %. Lease and non-lease components — In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance, taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in the period in which the costs are incurred. Below are the lease commitments for the next 5 years: Lease commitments Year Ending June 30 th Lease Expense 2023 $ 120,002 2024 246,004 2025 253,384 2026 260,985 2027 313,836 Less imputed interest ( 109,538 ) Total $ 1,084,673 Sublease Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sales-type or direct financing lease. The Company will recognize operating income from the sublease on a straight-line basis in its statements of operations over the sublease term. During the three and six months ended December 31, 2022 and 2021, the net operating lease expenses were as follows: Schedule of net operating lease expenses For the Three Months Ended For the Six Months Ended December 31, December 31, 2022 2021 2022 2021 Operating Lease Expense $ 96,730 $ 84,113 $ 140,660 $ 168,196 Sub lease Income ( 53,310 ) — ( 106,620 ) — Total Net Lease Expense $ 43,420 $ 84,113 $ 34,040 $ 168,196 Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2022, amounted to $ 43,420 and $ 34,040 , respectively. Lease expense charged to general and administrative expenses for the three and six months ended December 31, 2021, amounted to $ 84,113 and $ 168,196 , respectively. 14 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 7 — NOTES PAYABLE Convertible Notes Payable — On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to Paseco APS (the “Holder”), a Danish limited company and an existing stockholder of the Company each with a face value amount of $ 600,000 , convertible into shares of Common Stock, $ 0.0001 par value per share. The outstanding principal amount of the Convertible Notes was due and payable on February 6, 2023 . Interest on the Convertible Notes commenced accruing on the date of issuance at six percent ( 6 %) per annum, computed on the basis of twelve 30-day months, and is compounded monthly on the final day of each calendar month based upon the principal and all accrued and unpaid interest outstanding as of such compound date. The interest was payable in cash on a semi-annual basis. The holder of the Convertible Notes had the right at any time prior to the date that is twelve months from issuance to convert all or any part of the outstanding and unpaid principal and all unpaid interest into shares of the Company’s Common Stock. The conversion price was equal to $ 12.00 per share of Common Stock. The Holder did not exercise the conversion feature that expired on February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds received from the issuance have been recognized as a liability on the balance sheet. The Convertible Notes balance as of December 31, 2022 and 2021, was $ 1,200,000 . Effective December 30, 2022 (the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024 , and the interest was increased to twelve percent ( 12 %) per annum, which was prepaid by the Company in full on the date of amendment through the issuance of 198,439 shares of the Company’s Common Stock which is comprised of 29,419 shares for accrued interest up to the Effective Date and 169,020 shares related to the prepayment of interest through the extension date of the Amended and Restated Secured Notes using the closing market price on that date, of $ 1.03 . The obligations of the Company under the Amended and Restated Secured Notes were secured by a security agreement (the “Security Agreement”). The Company evaluated the Secured Notes and conversion feature to determine the appropriate accounting treatment based on the terms of the agreement. In accordance with ASC 480-Distinguising Liabilities from Equity, the Company determined that the Secured Notes embody an obligation that may require the Company to settle with the issuance of a variable number of shares, where the monetary value of the obligation is based predominantly on a fixed monetary amount $ 1,200,000 known at inception. Accordingly, the Company recorded the Secured Note as share settled debt. The total value of the shares issued were $ 204,392 which included $ 174,090 as prepaid interest and $ 30,302 for accrued interest as of December 30, 2022. As of December 31, 2022 and 2021, the Company recorded accrued interest in the amount of zero 0 and $ 24,181 , which is included in accrued expenses. For the three and six months ended December 31, 2022 the interest expense related to the Convertible Notes amounted to $ 18,272 and $ 36,453 respectively. For the three and six months ended December 31, 2021 the interest expense related to the Convertible Notes amounted to $ 18,181 and $ 36,453 respectively. Note Payable — On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $ 5,000,000 (the “Promissory Note”) to the Holder. The principal amount of the Promissory Note was originally payable on November 30, 2021 (the “Maturity Date”). The Promissory Note bore interest at a fixed rate of 6 % per annum, computed based on the number of days between the Issuance Date and the Maturity Date, which was prepaid by the Company in full on the Issuance Date through the issuance of 188,485 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $ 501,370 . The Company evaluated the Unsecured Note and PIK interest in accordance with ASC 470-Debt and ASC 835-Interest, respectively. Pursuant to ASC 470-20, proceeds received from the issuance are to be recognized at their relative fair value, thus the liability is shown net of the corresponding discount of $ 493,192 , which is the relative fair value of the shares issued for the PIK interest on the closing date using the effective interest method. The discount of $ 493,192 will be accreted over the life of the Promissory Note. On February 11, 2021, the Company entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022 . All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6 % per annum, which was prepaid by the Company in full on the date of the amendment through the issuance of 74,054 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $ 298,178 . On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 and increased the interest rate from 6 % to 12 % per annum. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 12% per annum. Pursuant to the amendment, the Company prepaid interest for the period November 30, 2022 until May 30, 2023 on the date of the amendment through the issuance of 47,115 shares of the Company’s Common Stock based on the closing market price on that date for a total value of $ 299,178 . All other accrued interest payable from May 30, 2023 to the Maturity Date shall be payable by the Company on May 30, 2023, at the option of the Holder either (i) in cash or (ii) in non-assessable shares of the Company’s Common Stock, valued at the closing sale price of the Common Stock of the Nasdaq Capital Market on May 30, 2023. Effective December 30, 2022, the Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral. For the three and six months ended December 31, 2022, discount amortization of $ 74,621 and $ 149,242 was charged to interest expense. For the three and six months ended December 31, 2021, discount amortization of $ 74,274 and $ 148,548 was charged to interest expense. The Promissory Note balance, net of discount at December 31, 2022 is $ 4,726,390 . Finance Agreement — On November 30, 2022, the Company entered into a premium finance agreement (the “Agreement”) related to insurance, which resulted into a prepaid expense with a principal amount of $ 1,139,875 at 6.69 % interest per annum. The repayment of the Agreement will be made in nine equal monthly installments of $ 96,220 . For the three and six months ended December 31, 2022 and 2021, the Company made repayments of $ 466,625 and $ 227,598 respectively. For the three and six months ended December 31, 2022, the Company recorded total interest expense in the amount of $ 2,782 . This amount is reflected in other income and expenses. Total interest expense recorded for the three and six months ended December 31, 2022, was $ 92,892 and $ 188,477 , respectively. Interest expense recorded for the three and six months ended December 31, 2021, was $ 93,382 and $ 183,121 , respectively. 15 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — STOCKHOLDERS’ EQUITY Preferred Stock —The Company has 10,000,000 authorized shares of Preferred Stock, par value $ 0.0001 per share. At December 31, 2022, and June 30, 2022, there were zero 0 shares issued and outstanding. Common Stock —The Company has 100,000,000 authorized shares of Common Stock, par value $ 0.0001 per share. At December 31, 2022, and June 30, 2022, there were 55,705,521 and 53,007,082 shares issued and outstanding, respectively. Voting — Holders of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors. Dividends — Holders of Common Stock are entitled to receive ratably such dividends as the Board from time to time may declare out of funds legally available. Liquidation Rights — In the event of any liquidation, dissolution or winding up of affairs of the Company, after payment of all debts and liabilities, the holders of Common Stock will be entitled to share ratably in the distribution of any of the remaining assets. Purchase Agreement with Lincoln Park Capital On July 8, 2020, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 of shares of Common Stock from time to time through August 1, 2023 . In consideration for entering into the Purchase Agreement, we issued 139,567 shares of Common Stock to Lincoln Park as a commitment fee on July 21, 2020. During the six months ended December 31, 2022 and 2021, we did no t sell any shares of Common Stock to Lincoln Park under the Purchase Agreement. As of October 17, 2022, we no longer have access to this Purchase Agreement as we are no longer able to use the registration statement on Form S-3 that registered the shares issuable to Lincoln Park under the Purchase Agreement. 16 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — STOCKHOLDERS’ EQUITY (Continued) Common Stock Issuances On July 14, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 shares of Common Stock for total proceeds to the Company of $ 1,625,000 , with corresponding earn-out distribution of the same number of shares in connection with the acquisition of Enochian BioPharma, Inc. This non-cash earn-out distribution impacted stockholders’ equity in the amount of $ 2,762,500 based on the share price on July 14, 2022 of $ 2.21 . In the three and six months ended December 31, 2022 there were 198,439 and 2,698,439 shares of Common Stock issued, respectively. The Company recorded a loss on extinguishment of contingent consideration liability of $ 419,182 during the six months ended December 31, 2022 which reflects the difference between the fair value of the shares and the contingent consideration liability at the time of extinguishment. As of December 31, 2022, all outstanding warrants have been exercised and there is no further contingent consideration liability balance remaining as of the end of this period. Acquisition of Enochian Biopharma Inc. / Contingently issuable shares — On February 16, 2018, the acquisition of Enochian Biopharma was completed. As part of the acquisition, the stockholders of Enochian Biopharma received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants, which were outstanding at closing. As of December 31, 2022, no further Contingent Shares are issuable. Acquisition of Enochian Denmark — At December 31, 2022, and June 30, 2022, the Company maintained a reserve of 17,414 shares of Common Stock of the Registrant held in escrow according to Danish law (the “Escrow Shares”), all of which are reflected as issued and outstanding in the accompanying financial statements. The Escrow Shares are reserved to acquire the shares of Enochian Denmark held by non-consenting shareholders of Enochian Denmark on both December 31, 2022, and June 30, 2022, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark. There have been 167,639 shares of Common Stock issued to non-consenting shareholders of Enochian Denmark as of December 31, 2022. During the three and six months ended December 31, 2022, the Company issued zero 0 shares of Common Stock to such non-consenting shareholders of Enochian Denmark. 17 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — STOCKHOLDERS’ EQUITY (Continued) Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended December 31, 2022: Summary of weighted-average assumptions used to estimate the fair values of the stock options granted Enochian Biosciences Inc. Expected term (in years) 5.3 – 6.5 Volatility 84.66 %- 90.75 % Risk free interest rate 2.70 %- 4.14 % Dividend yield 0 % The Company recognized stock-based compensation expense related to the options of $ 819,955 and $ 1,845,963 for the three and six months ended December 31, 2022, respectively. The Company recognized stock-based compensation expense related to the options of $ 2,043,292 and $ 4,771,267 for the three and six months ended December 31, 2021, respectively. At December 31, 2022, the Company had approximately $ 4,990,165 of unrecognized compensation cost related to non-vested options. Plan Options On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 shares of Common Stock for issuance in accordance with the terms of the 2014 Plan. On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted Enochian’s 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan authorized options to be awarded to not exceed the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan. Pursuant to the 2019 Plan, the Company granted options to purchase 178,000 shares of Common Stock to employees with a three-year vesting period during the three and six months ended December 31, 2022, respectively. For the three and six months ended December 31, 2021, the Company granted options to purchase 120,900 and 3,130,200 shares of Common Stock to employees with a three-year vesting period, respectively. During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 and 184,800 shares of Common stock to employees with a six-month vesting period, respectively. For the three and six months ended December 31, 2021, the Company did no t grant options to purchase shares of Common Stock to employees with a six-month vesting period. During the three and six months ended December 31, 2022, the Company granted options to purchase zero 0 and 73,200 shares of Common stock to employees with a one-year vesting period, respectively. For the three and six months ended December 31, 2021, the Company did no t grant options to purchase shares of Common Stock to employees with a one-year vesting period. During the three and six months ended December 31, 2022, the Company granted options to purchase 159,959 and 210,917 shares of Common Stock, to the Board of Directors and Scientific Advisory Board Members with a one-year vesting period, respectively. For the three and six months ended December 31, 2021, the Company granted options to purchase 36,727 and 63,462 shares of Common Stock to members of the Board of Directors and Scientific Advisory Board with a one-year vesting period, respectively. During the three and six months ended December 31, 2022, the Company did no t grant options to purchase shares of Common stock for consulting services. For the three and six months ended December 2021, the Company granted options to purchase 21,979 shares of Common Stock with immediate vesting, issued options to purchase 17,500 shares of Common Stock with a one-year vesting period, and issued options to purchase 60,000 shares of Common Stock with a three-year vesting period for consulting services. All of the above options are exercisable at the market price of the Company’s Common Stock on the date of the grant. To date the Company has granted options under the 2014 Plan and 2019 Plan (“Plan Options”) to purchase 5,475,559 shares of Common Stock. At December 31, 2022 the Company has 2,310,289 options available to be issued under the 2019 Plan. 18 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — STOCKHOLDERS’ EQUITY (Continued) A summary of the status of the Plan Options outstanding at December 31, 2022, is presented below : Summary of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 1.00 – 4.50 860,273 8.97 $ 2.40 217,064 6.83 $ 3.21 $ 4.51 – 6.50 3,169,769 8.20 $ 4.83 1,153,876 7.59 $ 5.26 $ 6.51 – 8.00 803,393 7.70 $ 8.02 604,414 7.24 $ 7.94 Total 4,833,436 8.26 $ 4.93 1,975,354 7.40 $ 5.85 A summary of the status of the Plan Options at December 31, 2022, and changes since July 1, 2022, are presented below: Summary of stock option activity Shares Weighted Average Exercise Price Average Remaining Life Weighted Average Intrinsic Value Outstanding at beginning of period 4,307,820 $ 5.37 8.55 $ — Granted 646,917 $ 2.07 Exercised — $ — Forfeited ( 121,300 ) $ 5.30 Expired/Canceled — $ — Outstanding at end of period 4,833,436 $ 4.93 8.26 $ — Exercisable at end of period 1,975,354 $ 5.85 7.40 $ — At December 31, 2022, the Company had 1,975,354 exercisable Plan Options outstanding. The total intrinsic value of options exercisable at December 31, 2022, was 0 zero. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at December 31, 2022 (for outstanding options), less the applicable exercise price. Common Stock Purchase Warrants A summary of the warrants outstanding at December 31, 2022, and changes since July 1, 2022, are presented below: Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Price Weighted Average Remaining Life Outstanding at beginning of period 1,250,000 $ 1.30 1.02 Granted — $ — — Exercised ( 1,250,000 ) $ 1.30 — Cancelled/Expired — $ — — Outstanding and exercisable at end of period — $ — — 19 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — STOCKHOLDERS’ EQUITY (Continued) Restricted Stock Units (RSUs) The Company recognized stock-based compensation expense related to RSUs of zero 0 for both the three and six months ended December 31, 2022. The Company recognized stock-based compensation expense related to the RSUs of $ 255,340 and $ 258,331 for the three and six months ended December 31, 2021, respectively. 20 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 9 — COMMITMENTS AND CONTINGENCIES Commitments On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $ 130,000 per month. Upon the completion of the 20 months, the monthly consulting fee of $25,000 continued for scientific consulting and knowledge transfer on existing HIV experiments until the services were no longer being rendered or the G-Tech Agreement is terminated. As of May 25, 2022, the consultant was no longer able to render services, therefore no expense was incurred for the three and six months ended December 31, 2022. For the three and six months ended December 31, 2021, $75,000 and $150,000 was charged to research and development expenses in our Condensed Consolidated Statements of Operations related to this consulting agreement. On January 31, 2020, the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections. The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $ 1.2 million within 7 days of January 31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides for cooperation related to the development of intellectual property related to the Treatment and for a 2 % royalty to G-Tech on any net sales that may occur under the HBV License. On February 6, 2020, the Company paid the $ 1.2 million up-front payment. The HBV License Agreement contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the HBV License. The cash funding for research costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made after January 31, 2022. During the three and six months ended December 31, 2022 the Company paid a total of zero 0 and during the three and six months ended December 31, 2021, the Company paid $ 433,500 and $ 867,000 , respectively, for scientific staffing resources, research and development and Investigational New Drug (IND) Enabling studies. During the three and six months ended December 31, 2022, the Company paid zero 0 for any type of milestone. During the three and six months ended December 31, 2021 the Company paid zero 0 and $ 1,500,000 , respectively, for the milestone completion of a Pre-IND process following receipt of written comments in accordance the HBV License Agreement. The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section below). On April 18, 2021, the Company entered into a Statement of Work and License Agreement (the “License Agreement”), by and among the Company, G-Tech and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”) to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the “Prevention and Treatment”). The License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 and a $ 760,000 payment for expenditures to date prior to the effective date related to research towards the Prevention and Treatment within 60 days of April 18, 2021. The License Agreement provides for additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the License Agreement, in each case subject to the terms of the License Agreement. 21 The License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G Tech on any net sales that may occur under the License Agreement. For both the three and six months ended December 31, 2022, the Company paid zero 0 related to this License Agreement. During the three and six months ended December 31, 2021 the Company paid $ 75,000 and $ 150,000 related to the Prevention and Treatment research. The Company is no longer pursuing any product candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license (see Contingencies sub-section below). On August 25, 2021, the Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application, to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $ 600,000 and agreed to fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC License Agreement, the Company paid the initial payment of $ 600,000 . G-Tech and SRI are controlled by Serhat Gümrükcü and Anderson Wittekind, shareholders of the Company. Shares held for non-consenting shareholders – The 17,414 remaining shares of Common Stock related to the Acquisition of Enochian Denmark have been reflected as issued and outstanding in the accompanying financial statements. There were zero 0 shares of Common Stock issued to such non-consenting shareholders during the three and six months ended December 31, 2022 (see Note 8.) Service Agreements – The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis. This consulting agreement was terminated as of October 31, 2022. The Company maintains employment agreements with other staff in the ordinary course of business. Contingencies Securities Class Action Litigation . On July 26, 2022 and July 28, 2022, securities class action complaints were filed by purported stockholders of ours in the United States District Court for the Central District of California against us and certain of our current and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs. The defendants have not yet responded to the complaints. 22 Federal Derivative Litigation . On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants’ anticipated motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint. State Derivative Litigation . On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The action also names the Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution, and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. The defendants have not yet responded to the complaint. On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind, G-Tech Bio LLC, SG & AW Holdings LLC, and Seraph Research Institute. The Complaint alleges that the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” The defendants have not yet answered the allegations set forth in the Company’s complaint. On December 28, 2022, the Company received a demand letter on behalf of Weird Science LLC (“Weird Science”), William Anderson Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust alleging that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS. Specifically, the demand letter alleges that the Company “breached its obligations under the Investor Rights Agreement to provide the requisite thirty days’ notice” to Holders of Registrable Securities in connection with SEC Form S-3 filings on July 13, 2020 and February 11, 2022 and demands over $64 million in damages. The Company denies these allegations and intends to vigorously defend against this claim. On March 1, 2021, former Enochian BioSciences Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Enochian BioSciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Enochian BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim. 23 ENOCHIAN BIOSCIENCES INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 10 — RELATED PARTY TRANSACTIONS There were no payments made to G-Tech by the Company for the three and six months ended December 31, 2022. For the three and six months ended December 31, 2021, the Company paid G-Tech $ 718,500 and 3,537,000 , respectively, which included payments for consulting agreements related to HIV, and contractual costs related to the HBV License, the Development License, the ALC License (see Note 9), and security expenses. NOTE 11 — SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company performed a review of events subsequent to the balance sheet date through the date of this report and determined that there were no such events requiring recognition or disclosure. 24 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Forward-Looking Statement Notice Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of Enochian Biosciences Inc. (“Enochian,” and together with its subsidiaries, the “Company”, “we” or “us”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the risks and uncertainties discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K as filed with the SEC on February 27, 2023. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of the business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Our Business We are a biotechnology company committed to developing advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. Our Product Development strategy is anchored in the use of “non-self” or allogeneic cells that enhance the immune response that we seek to elicit. Over the past several years, Enochian BioSciences has evolved from a company with a single product candidate as a potential cure for HIV (ENOB-HV-01), adding two additional pipeline candidates for HIV (ENOB-HV-12 and ENOB-HV-21), a pipeline for Hepatitis B Virus (HBV) (ENOB-HB-01), and with a significant expansion into cancer immune therapies to address high unmet needs from difficult-to- treat solid tumors (ENOB-DC-11.) The oncology platform is now at the forefront of our development activities, beginning with pancreatic cancer. Many operational aspects of our platforms can be quickly adapted to multiple disease states from a single therapeutic approach, potentially streamlining and accelerating development, and regulatory process, as well as manufacturing operations. Moreover, because our product candidates do not require specialized delivery devices and surgical procedures, our potentially groundbreaking interventions could have worldwide applicability. The Company responds quickly to new data and perceived development opportunities and risks assessments. Based on the maturation of our pipelines, the Company makes business decisions to prioritize the programs that could move more rapidly through development and commercial processes. Therapeutic Platforms The Company’s general approach with gene- and/or cell-therapy is to enhance the immune system to allow a person to better fight diseases. The Company is leveraging general principals and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote the recognition and elimination of diseased cells. 25 Advanced Allogeneic Cell Therapy The strategic benefit of cell therapy platforms is to potentially allow for manufacture of large, “off-the-shelf” banks of therapeutic cells that could be accessed on demand by health care professionals to potentially decrease the time between diagnosis and treatment. In addition, because we focus on cells from donors the strategy could potentially enhance the ability of the therapeutic candidates to induce a more robust response once injected into patients. The human immune system is designed to recognize and distinguish “self” from “non-self” and destroy “otherness” such as bacteria, viruses, and damaged or diseased cells such as cancer cells. Alloreactivity (reacting against another person’s cells) is the most powerful response the immune system generates. Several of our technologies take advantage of the alloreactivity to hyper stimulate a person’s immune response to better attack a chronic infection (e.g., HIV) or solid tumor. In certain treatments (e.g., HIV and cancer), cells taken from healthy donors are sometimes genetically modified to introduce signaling molecules that are designed to enhance the ability of specific immune cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells. The Company believes that the combination of off-the-shelf allogeneic cells, combined with genetic modifications designed to enhance immune signaling, could potentially generate therapeutic candidates that have unique attributes that will increase the likelihood of success. Cell Therapy enabling technology In addition to the platform described above, Enochian BioSciences has an innovative gene therapy approach to enhance the selection and engraftment (uptake) of cells carrying therapeutic attributes. Enhanced uptake or engraftment could play a critical role in some cases to increase the likelihood of therapeutic benefit. This technology was initially developed for autologous cell therapy from a person living with HIV, and genetically modifying those cells so they cannot be infected with most variants of HIV plus a gene modification to enhance uptake. We have sublicensed under a profit-sharing agreement our technology to potentially increase engraftment for potential use in CAR-T therapy as a potential cure for HIV. HBV Gene Therapy Enochian BioSciences is exploring various approaches for gene therapy design elements to potentially eliminate virus-infected cells with an innovative molecular mechanism that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection to exacerbate disease. Oncology: ENOB-DC-11: Genetically modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors – Starting with Pancreatic Cancer Allogeneic Cell Therapy Platform –moderately Advanced Pre-Clinical Based on learning from peer-reviewed publications of Phase I/IIa trials, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission from some of the deadliest solid tumors. The survival rate in pancreatic cancer is currently only 5 to 10 percent at 5 years. Initial preclinical in vitro and proof of concept in vivo studies have been encouraging. The platform might also allow for non-specific immune enhancement that could have impact against a broad array of solid tumors. We initially plan to target pancreatic cancer. Other potential targets for later development could include triple-negative breast cancer, glioblastoma, or renal cell carcinoma. As with HIV, our approach would potentially allow for outpatient therapy without wiping out or significantly impairing the patient’s immune system, as many current approaches require. Enochian BioSciences has initiated a collaboration with Dr. Anahid Jewett from UCLA to study further the in vitro and in vivo effectiveness of the approach in pancreatic cancer. Dr. Jewett created an innovative pancreatic cancer mouse model that mimics the human immune system in combination with implanted human cancer cells. Early results show promising substantial tumor size reduction. We are now fully committed to process development/improvements and hope to have confirmatory in vivo data by early 2023 with potential Pre-IND submission early/mid 2023. If successful, clinical trials in humans could be possible by the first half of 2024. 26 ENOB-DC-12--XX: Genetically modified Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Additional Indications The technology is a platform that could potentially be adapted to other solid tumors first line and/or salvage therapy, by itself or, potentially, in combination with other cancer treatments. Additional indications are being evaluated strategically to balance risk and opportunity to advance therapeutic development quickly in cancer indications with few treatment options. Infectious Diseases: HIV: ENOB-HV 12: HIV Therapeutic Vaccines for Potential Long-term Remission/Cure Allogeneic Cell Therapy Platform - Advanced Pre-Clinical Stage; Non-Human Primate Studies Ongoing. In persons living with HIV who are controlling the spread of virus with anti-retroviral (ARV) treatment, boosting the immune system in a different way than the virus already has through infection, could allow for control of HIV after stopping ARVs. Enochian BioSciences is developing ENOB-HV-12 that utilizes a novel cellular and immunotherapy approach that could potentially provide therapeutic vaccines for HIV (ENOB-HV-12). A non-human primate study of the therapeutic vaccine in primates at the Fred Hutchinson Cancer Research Center is ongoing. Animals began receiving the first injections of the potential therapeutic vaccine in August, 2022. Preliminary results could potentially be available in the first half of 2023. A Pre-IND request could be submitted by mid-2023, with IND submission and the beginning of Phase I clinical trials by mid- to end-2024. ENOB-HV-01: Autologous Transplant with Genetically Modified Cells : FDA INTERACT Meeting Held February 2020 - Advanced Pre-Clinical Stage We have pioneered a novel enabling technology (ALDH gene modification) that we believe will allow sufficient engraftment of the CCR5 gene-modified Hematopoietic Stem Cell (HSC) to eliminate the need for Antiretroviral Treatment (ART.) Management conducted a successful FDA INTERACT Meeting in alignment with the Company’s experimental plan. Although in vitro and in vivo studies have demonstrated promising results, further development of ENOB-HV-01 at this time was deemed costly and a long-term undertaking. While the Company plans to return to full development of the approach when resources are available, it has become less attractive and been deprioritized for business reasons, while pipelines that could move more quickly have been prioritized (e.g., DC-11). Therefore, a business decision was made to sub-license the ALDH gene modification. ENOB-HV-01 was sub-licensed to Caring Cross with a profit share arrangement. Caring Cross is developing a CAR-T approach that they believe, when combined with Enochian Biosciences ALDH gene modification, could enhance engraftment of their CAR-T cell therapy and enhance their likelihood of success. ENOB-HV-21: Immunotherapy with Allogeneic NK/GDT Cells Allogeneic Cell Therapy Platform -Pre-IND conducted - Advanced Pre-Clinical with Human Data through a Collaboration We are also exploring ENOB-HV-21, an innovative treatment for HIV with allogeneic Natural Killer (NK) and Gamma Delta T-Cells (GDT). It is believed that the GDT cells, a small subset of immune cells that can be infected with HIV, could both be infected by, and be a key factor in controlling the virus. The initial scientific findings were presented during the American Society of Gene & Cell Therapy (ASCGT) Annual Meeting in 2021. Enochian BioSciences has an exclusive license to use the underlying patent to develop ENOB-HV-21 for potential treatment or cure of HIV. A successful investigator-initiated Pre-IND was completed in October 2021. However, due to a shift in priorities to the Oncology pipeline, Enochian BioSciences does not plan to pursue the IND and potential clinical trial in the near to medium-term. 27 HBV: ENOB-HB-01: Potential Cure for HBV HBV Gene Therapy -Pre-Clinical ENOB-HB-01 is in an early pre-clinical phase as we explore various approaches for gene therapy design elements. If those explorations are successful, it is possible we could begin the regulatory process at the earliest in the first half of 2024. However, our highest priority is currently the oncology platform, beginning with pancreatic cancer. Corporate History We were incorporated under the laws of the State of Delaware on January 18, 2011, under the name Putnam Hills Corp. and in 2014 we merged with and changed our name to DanDrit Biotech USA, Inc. In 2018, we acquired Enochian Biopharma and changed our name to Enochian BioSciences Inc. Regaining Compliance with Nasdaq Listing Requirements On each of October 17, 2022, November 23, 2022, and February 16, 2022, we received a notice, or the Notices, from the Listing Qualifications Department of Nasdaq stating that we were not in compliance with Nasdaq Listing Rule 5250(c)(1), or the “Rule”, because we did not timely file our Form 10-K for the period ended June 30, 2022 and our Forms 10-Q for the periods ended September 30, 2022 and December 31, 2022 with the SEC. The Rule requires listed companies to timely file all required periodic financial reports with the SEC. On February 27, 2023, we filed our Form 10-K. On March 7, 2023 we filed our Form 10-Q for the period ended September 30, 2022 but have not yet filed our Form 10-Q for the period ended December 31, 2022, and therefore we have not regained compliance with the Rule. We were unable to file the Annual Report on Form 10-K for the period ended June 30, 2022 and the Quarterly Report on Form 10-Q for the periods ended September 30, 2022 and December 31, 2022 by their initial deadlines, due to the reasons described in the Notifications of Late Filing on Form 12b-25, filed with the SEC on September 29, 2022 and November 15, 2022. If we are unable to maintain compliance with the Rule or with any of the other continued listing requirements, Nasdaq may take steps to delist our securities, which could have adverse consequences, including a limited availability of market quotations for our securities, reduced liquidity for our securities, a limited amount of news and analyst coverage and a decreased ability to issue additional securities or obtain additional financing in the future. Going Concern and Management’s Plans The financial statements included elsewhere herein for the period ended December 31, 2022, were prepared under the assumption that we would continue our operations as a going concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. As of December 31, 2022, we had cash and cash equivalents of $4,118,896, an accumulated deficit of $216,502,705, and total liabilities of $13,374,307. We have incurred losses from continuing operations, have used cash in our continuing operations, and are dependent on additional financing to fund operations. These conditions raise substantial doubt about our ability to continue as a going concern for one year after the date the financial statements are issued. The financial statements included elsewhere herein do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. 28 Management has reduced overhead and administrative costs by streamlining the organization to focus around two of its therapies (oncology and a HIV therapeutic vaccine). The Company has tailored its workforce to focus on these therapies. In addition, management has extended its $1.2 million convertible notes 12 months out to be payable on February 28, 2024, and the Company intends to attempt to secure additional required funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us. Funding that we may receive during fiscal 2023 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support commercialization of our products and conduct the clinical and regulatory work to develop our product candidates, and to begin building working capital reserves. COVID-19 The COVID-19 pandemic continues to evolve. COVID-19 may cause delays in our research activities. To date, the COVID-19 pandemic has not materially affected our operations. However, it has caused delays in the conduct of experiments due to limitations in resources and supply chain issues, in particular for those conducting experiments. There have also been increases in the cost to conduct animal studies due to staffing and other limitations. The full extent to which the COVID-19 pandemic may impact our business and operations is subject to future developments, which are uncertain and difficult to predict. We continue to monitor the impact of the COVID-19 pandemic on our business and operations and will seek to adjust our activities as appropriate. 29 Results of Operations for the three and six months ended December 31, 2022, compared to the three and six months ended December 31, 2021 The following table sets forth our revenues, expenses, and net loss for the three and six months ended December 31, 2022, and 2021. The financial information below is derived from our unaudited condensed consolidated financial statements. For the Three Months Ended For the Six Months Ended December 31, Increase/(Decrease) December 31, Increase/(Decrease) 2022 2021 $ % 2022 2021 $ % Operating Expenses General and administrative 4,013,063 3,961,764 51,299 1 % 8,569,903 8,379,268 190,635 2 % Research and development 325,959 2,337,222 (2,011,263 ) (86 )% 2,931,334 5,392,658 (2,461,324 ) (46 )% Depreciation and amortization 28,844 31,805 (2,961 ) (9 )% 57,245 63,538 (6,293 ) (10 )% Total Operating Expenses $ 4,367,866 $ 6,330,791 $ (1,962,925 ) (31 )% $ 11,558,482 $ 13,835,464 $ (2,276,982 ) (16 )% LOSS FROM OPERATIONS $ (4,367,866 ) $ (6,330,791 ) $ (1,962,925 ) (31 )% $ (11,558,482 ) $ (13,835,464 ) $ 2,276,982 (16 )% Other Income (Expenses) Change in fair value of contingent consideration — (167,255 ) 167,255 (100 )% — (2,991,897 ) 2,991,897 (100 )% Loss on extinguishment of contingent consideration liability — — — 0 % (419,182 ) — (419,182 ) (100 )% Interest expense (92,892 ) (93,382 ) 490 (1 )% (188,477 ) (183,121 ) (5,356 ) 3 % Gain (Loss) on currency transactions — — — 0 % — 9 (9 ) 100 % Interest and other income 3,010 8,487 (5,477 ) (65 )% 8,633 15,597 (6,964 ) (45 )% Total Other Income (Expenses) (89,882 ) (252,150 ) 162,268 (64 )% (599,026 ) (3,159,412 ) 2,560,386 (81 )% Loss Before Income Taxes $ (4,457,748 ) $ (6,582,941 ) $ 2,125,193 (32 )% $ (12,157,508 ) $ (16,994,876 ) $ (4,837,368 ) (28 )% Income Tax (Expense) Benefit $ — $ — $ — 0 % $ — $ (34 ) $ 34 100 % NET LOSS $ (4,457,748 ) $ (6,582,941 ) $ (2,125,193 ) (32 )% $ (12,157,508 ) $ (16,994,910 ) $ 4,837,402 (28 )% Revenues We are a pre-revenue, pre-clinical biotechnology company. We have never generated revenues and have incurred losses since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale. Expenses Our operating expenses for the three months ended December 31, 2022, and 2021, were $4,367,866 and $6,330,791 respectively, representing a decrease of $1,962,925, or approximately 31%. The decrease in operating expenses primarily relates to a decrease in research and development expenses of $2,011,263 partially offset by an increase in general and administrative expenses of $51,299. Our operating expenses for the six months ended December 31, 2022, and 2021, were $11,558,482 and $13,835,464, respectively, representing a decrease of $2,276,982 or approximately 16%. The decrease in operating expenses primarily relates to a decrease in research and development expenses of $2,461,324, partially offset by an increase in general and administrative expenses of $190,635. 30 General and administrative expenses for the three months ended December 31, 2022, and 2021, were $4,013,063 and $3,961,764, respectively, representing an increase of $51,299 or approximately 1%. The variance is related to an increase in legal expenses of $1,115,456 and compensation and related expenses of $243,919, partially offset by a decrease in stock-based compensation of $1,223,337. General and administrative expenses for the six months ended December 31, 2022, and 2021, were $8,569,903 and $8,379,268, respectively, representing an increase of $190,635 or approximately 2%. The variance primarily relates to an increase in legal expenses of $2,393,807 and compensation and related expenses of $906,299, partially offset by a decrease in stock-based compensation of $2,925,304. Research and development expenses for the three months ended December 31, 2022, and 2021, were $325,959 and $2,337,222, respectively, representing a decrease of $2,011,263 or approximately 86%. The variance is primarily driven by a decrease of $508,500 in expenses related to payments made to a related party for an abandoned product candidate, and $1,273,343 in collaborating partner expenses with CDMO and CRO partners incurred in the prior period. Research and development expenses for the six months ended December 31, 2022, and 2021, were $2,931,334 and $5,392,658, respectively, representing a decrease of $2,461,324 or approximately 46%. The variance is primarily driven by a decrease of $3,117,000 in expenses related to payments made to a related party for an abandoned product candidate, $381,986 in consulting expenses, and $226,562 in lab related expenses partially offset by an increase of $1,365,557 in collaborating partner expenses with CDMO and CRO partners. The Company recorded other expense of $89,882 for the three months ended December 31, 2022, compared to other expense of $252,150 for the three months ended December 31, 2021, representing a decrease in other expense of $162,268 or 64%. The variance is primarily due to the change in fair value of the contingent consideration liability expense of $167,255 incurred in the prior period. The contingent consideration liability was settled in the period ending September 30, 2022. The Company recorded other expense of $599,026 for the six months ended December 31, 2022, compared to other expense of $3,159,412 for the six months ended December 31, 2021, representing a decrease in other expense of $2,560,386 or 81%. The variance is primarily due to the change in fair value of the contingent consideration liability expense of $2,991,897, in the prior period net of a loss of $419,182 related to the extinguishment of the contingent consideration liability during the period ending September 30, 2022. Net Loss Net loss for the three months ended December 31, 2022, and 2021, was $4,457,748 and $6,582,941, respectively, representing a decrease in loss of $2,125,193 or approximately 32%. The decrease in net loss was primarily due to a decrease in research and development expenses of $2,011,263 and a decrease in expense related to the change in fair value of contingent consideration of $167,255. Net loss for the six months ended December 31, 2022, and 2021, was $12,157,508 and $16,994,910, respectively, representing a decrease in loss of $4,837,402 or approximately 28%. The decrease in net loss was primarily due to a decrease in research and development expenses of $2,461,324, and a decrease in expense related to the change in fair value of contingent consideration of $2,991,897. Liquidity and Capital Resources We have historically satisfied our capital and liquidity requirements through funding from stockholders, the sale of our Common Stock and warrants, and debt financing. We have never generated any sales revenue to support our operations and we expect this to continue until our therapies or products are approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved for sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be profitable. As noted above under the heading “Going Concern and Management’s Plans,” through December 31, 2022, we have incurred substantial losses. We will need additional funds for (a) research and development, (b) increases in personnel, and (c) the purchase of equipment, specifically to advance towards an Investigational New Drug Application (IND) following Pre-IND readouts from the FDA for ENOB-DC11, ENOB-HV-12, ENOB-HV-01, ENOB-HV-21 and ENOB-HB-01. The availability of any required additional funding cannot be assured. In addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in the future may be involved could adversely affect our liquidity and financial position. If additional funds are required, we may raise such funds from time to time through public or private sales of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely affect our growth plans and our financial condition and results of operations. 31 As of December 31, 2022, the Company had $4,118,896 in cash and working capital of $(5,902,533) as compared to $9,172,142 in cash and working capital of $3,114,170 as of June 30, 2022, a decrease of 55% and 290%, respectively. Assets Total assets at December 31, 2022, were $80,273,663 compared to $84,632,663 as of June 30, 2022. The decrease in total assets was primarily due to the decrease in cash of $5,053,246. The change in cash is primarily attributed to $2,931,334 in research and development costs related primarily to CDMO and CRO costs, along with approximately $6,666,695 in general and administrative expenses, net of non-cash items, partially offset by an increase in accounts payable of $3,153,358 due to the timing of cash payments and funding totaling $1,625,000 related to warrants exercised during the period. Liabilities Total liabilities at December 31, 2022, were $13,374,307 compared to $12,013,815 as of June 30, 2022. The increase in total liabilities was primarily related to an increase of $3,153,358 in accounts payable due to timing of cash payments and $654,730 in other current liabilities related to a financing arrangement for an insurance policy partially offset by the reduction in the contingent consideration liability of $2,343,318. The following is a summary of the Company’s cash flows (used in) or provided by operating, investing, and financing activities: Six Months Ended December 31, 2022 Six Months Ended December 31, 2021 Net Cash Used in Operating Activities $ (6,205,145 ) $ (9,897,151 ) Net Cash Used in Investing Activities (23,633 ) (5,156 ) Net Cash Provided by Financing Activities 1,158,375 2,950,741 Effect of exchange rates on cash 17,157 (4,937) Change in Cash and Cash Equivalents $ (5,053,246 ) $ (6,956,503 ) Cash Flows Cash used in operating activities for the six months ended December 31, 2022, and 2021 was ($6,205,145) and ($9,897,151), respectively. Cash used in operating activities during the current period included $2,931,334 in research and development expenses for related CDMO and CRO costs, along with approximately $6,666,695 in general and administrative expenses, net of non-cash items, partially offset by an increase in accounts payable of $3,153,358 due to the timing of cash payments. Cash provided by financing activities for the six months ended December 31, 2022, was $1,158,375 as compared to cash provided by financing activities of $2,950,741 during the six months ended December 31, 2021. During the six months ended December 31, 2022, the Company received financing from the exercise of warrants held by shareholders of $1,625,000 that was partially offset by repayments of a financing agreement of $466,625. Off-Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. 32 Significant Accounting Policies and Critical Accounting Estimates The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. For a summary of our accounting policies, see Note 1 to the unaudited condensed consolidated financial statements. Item 3. Quantitative and Qualitative Disclosures About Market Risk. As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”) are responsible for establishing and maintaining disclosure controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which this Report was prepared. The Certifying Officers are responsible for establishing and maintaining adequate internal control over financial reporting for the Company and used the “Internal Control over Financial Reporting Integrated Framework” issued by the Committee of Sponsoring Organizations (“COSO”) to conduct an extensive review of the Company’s “disclosure controls and procedures” (as defined in the Exchange Act, Rules 13a-15(e) and 15-d-15(e)) as of the end of each of the periods covered by this Report (the “Evaluation Date”). Based upon that evaluation, the Certifying Officers concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective in ensuring that the information we were required to disclose in reports that we file or submit under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. The deficiency is attributed to the Company not having adequate resources to address complex accounting matters. This control deficiency will be monitored, and attention will be given to this matter as we grow. The Certifying Officers based their conclusion on the fact that the Company has identified a material weakness in controls over financial reporting, detailed above. We expect to be deficient in our disclosure controls and procedures until sufficient capital is available to hire the appropriate internal accounting staff. Changes in Internal Controls There have been no changes in our internal controls over financial reporting during the three months ended December 31, 2022, that have materially affected or are reasonably likely to materially affect our internal controls. 33 PART II — OTHER INFORMATION Item 1. Legal Proceedings. Securities Class Action Litigation . On July 26, 2022 and July 28, 2022, securities class action complaints were filed by purported stockholders of ours in the United States District Court for the Central District of California against us and certain of our current and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs. The defendants have not yet responded to the complaints. Federal Derivative Litigation . On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District of California. On January 19, 2023, John Solak filed a substantially similar shareholder derivative action in the United States District Court for the District of Delaware. Both derivative actions recite similar underlying facts as those alleged in the Securities Class Action Litigation. The actions, filed on behalf of the Company, name Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The actions also name the Company as a nominal defendant. The actions allege violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also set out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiffs do not quantify any alleged injury, but seek damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court for the Central District of California stayed the Koenig matter pending resolution of the defendants’ anticipated motion to dismiss in the Securities Class Action Litigation. The defendants have not yet responded to either complaint. State Derivative Litigation . On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County, reciting similar underlying facts as those alleged in the Securities Class Action Litigation. The action, filed on behalf of the Company, names Serhat Gümrükcü and certain of the Company’s current and former directors as defendants. The action also names the Company as a nominal defendant. The action sets out claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. The defendants have not yet responded to the complaint. On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind, G Tech Bio LLC, SG & AW Holdings LLC, and Seraph Research Institute. The Complaint alleges that the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” The defendants have not yet answered the allegations set forth in the Company’s Complaint. On December 28, 2022, the Company received a demand letter on behalf of Weird Science LLC (“Weird Science”), William Anderson Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust alleging that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS. Specifically, the demand letter alleges that the Company “breached its obligations under the Investor Rights Agreement to provide the requisite thirty days’ notice” to Holders of Registrable Securities in connection with SEC Form S-3 filings on July 13, 2020 and February 11, 2022 and demands over $64 million in damages. The Company denies these allegations and intends to vigorously defend against this claim. On March 1, 2021, former Enochian BioSciences Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Enochian BioSciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Enochian BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim. 34 Item 1A. Risk Factors. Risk factors that may affect our business and financial results are discussed within Item 1A ”Risk Factors” of our annual report for the fiscal year ended June 30, 2022, on Form 10-K (“2022 Form 10-K”) filed with the SEC on February 27, 2023. There have been no material changes to the disclosures relating to this item from those set forth in our 2022 Form 10-K. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. None. Item 6. Exhibits. (a) Exhibits required by Item 601 of Regulation S-K. Exhibit No. Description 10.1 Form of Amended and Restated Senior Secured Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on February 23, 2023) 10.2 Amendment No. 3 to Promissory Note, effective December 30, 2022 (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on February 23, 2023) 10.3 † Security Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K filed with the SEC on February 23, 2023) 31.1** Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 , as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2** Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 , as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1*** Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2*** Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema 101.CAL XBRL Taxonomy Extension Calculation Linkbase 101.DEF XBRL Taxonomy Extension Definition Linkbase 101.LAB XBRL Taxonomy Extension Label Linkbase 101.PRE XBRL Taxonomy Extension Presentation Linkbase ** Filed herewith. *** Furnished herewith. † Schedules and similar attachments to this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such omitted materials to the SEC upon request. 35 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 9, 2023 ENOCHIAN BIOSCIENCES INC. By: /s/ Mark Dybul Mark Dybul Chief Executive Officer (Principal Executive Officer) By: /s/ Luisa Puche Luisa Puche Chief Financial Officer (Principal Financial and Accounting Officer) 36